Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Detailed Look At RVD Therapy In Newly Diagnosed Multiple Myeloma Patients

Home/Uncategorized/Detailed Look At RVD Therapy In Newly Diagnosed Multiple Myeloma Patients

Detailed Look At RVD Therapy In Newly Diagnosed Multiple Myeloma Patients

 I have included studies done by Mayo Clinic’s Dr. Keith Stewart in the past.  Here is a follow-up article, published in Blood, which discusses the history of developing the successful combination of Revlimid, Velcade and dexamethasone (RVD) in treating newly diagnosed multiple myeloma patients:

Union of forces advances myeloma care

A. Keith Stewart MAYO CLINIC
In this issue of Blood, Richardson et al report on a landmarktreatment regimen for newly diagnosed myeloma patients thatfor the first time combines lenalidomide and bortezomib. Thiseffort required a team approach comprising 2 competing pharmaceuticalcompanies (joining forces to study this promising regimen) andmultiple academic medical centers.1
Together, this team conceived of a winning combination chemotherapyregimen using lenalidomide, bortezomib, and dexamethasone (RVD)in newly diagnosed myeloma patients. An unprecedented 100% ofpatients treated at the defined phase 2 dose level respondedto treatment: 74% of patients experienced a 90% reduction intumor burden and 57% entered a complete remission (CR) withina few months of starting treatment. Comparable results havepreviously been reported only after comparatively toxic regimensinvolving intensive rounds of combination chemotherapy and repeateddoses of high-dose melphalan supported by autologous stem celltransplantation.2,3 It is noteworthy that the RVD regimen oftentook more than 4 cycles of therapy to achieve maximal response,with an upgrade in response occurring in 75% of patients whocontinued therapy up to 8 cycles and in half of the patientstreated for more than 8 cycles.

Read the rest by going to:  Use of RVD in newly diagnosed multiple myeloma patients.
Feel good and keep smiling!  Pat